The collaboration is aimed at deploying tablets at the point of care. CaerVision has allocated USD3.5m for this project.
Under the partnership CaerVision is expected to fund the purchase of the tablets and both firms will collaborate on sales and marketing efforts. This move also influences CaerVision's network of more than 1,000 Health Care Providers.
Perrigo to acquire United States rights for Entocort from AstraZeneca
US FDA approves Boehringer Ingelheim's Pradaxa
Phase II clinical trial for potential treatment of androgenetic alopecia completed by Samumed
Life Sciences Partners collaborates on immuno-oncology with Bristol-Myers Squibb
Arsanis initiates first cohort in Phase one clinical trial of ASN100
Impax introduces generic Avodart (Dutasteride) Capsules, 0.5 mg
Mylan unveils generic FazaClo orally disintegrating tablets for treating schizophrenia